MABF838
Anti-FcgRII/III Anibody, clone Ab93
clone 93, from rat
Synonym(s):
Low affinity immunoglobulin gamma Fc region receptor III, IgG Fc receptor III, Fc-gamma RIII, FcRIII, CD16, FcgRII/III, Low affinity immunoglobulin gamma Fc region receptor II, Fc gamma receptor IIB, Fc-gamma RII, Fc-gamma-RIIB, FcRII, IgG Fc receptor II
Select a Size
About This Item
biological source
rat
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
93, monoclonal
species reactivity
mouse
technique(s)
activity assay: suitable
flow cytometry: suitable
immunocytochemistry: suitable
isotype
IgG2aκ
NCBI accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
mouse ... Fcgr2b(14130), Fcgr3(14131)
Related Categories
General description
Immunogen
Application
Activity Assay Analysis: A representative lot prevented CD38-mediated proliferation of spleen-derived primary murine B-cells from wild-type, but not FcgammaRIl-deficient mice (Oliver, A.M., et al. (1999). Hybridoma 18(2):113-119).
Immunocytochemistry Analysis: A representative lot detected FcgRII association with cross-linkinked CD38 following anti-CD38 addition to cultured primary murine B-cells by fluorescent immunocytochemistry (Oliver, A.M., et al. (1999). Hybridoma 18(2):113-119).
Biochem/physiol Actions
Physical form
Analysis Note
Flow Cytometry Analysis: 5.0 µg of this antibody detected FcgRII/III in mouse splenocytes.
Other Notes
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service